AKT in cancer: new molecular insights and advances in drug development

The phosphatidylinositol‐3 kinase (PI3K)–AKT pathway is one of the most commonly dysregulated pathways in all of cancer, with somatic mutations, copy number alterations, aberrant epigenetic regulation and increased expression in a number of cancers. The carefully maintained homeostatic balance of cell division and growth on one hand, and programmed cell death on the other, is universally disturbed in tumorigenesis, and downstream effectors of the PI3K–AKT pathway play an important role in this disturbance. With a wide array of downstream effectors involved in cell survival and proliferation, the well‐characterized direct interactions of AKT make it a highly attractive yet elusive target for cancer therapy. Here, we review the salient features of this pathway, evidence of its role in promoting tumorigenesis and recent progress in the development of therapeutic agents that target AKT.

[1]  M. Ellis,et al.  A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer , 2016, Clinical Cancer Research.

[2]  J. Testa,et al.  Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.

[3]  J. Schellens,et al.  A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. , 2015 .

[4]  J. Wysolmerski,et al.  Mammary ductal and alveolar development: Lesson learned from genetically manipulated mice , 2001, Microscopy research and technique.

[5]  Xuan Sun,et al.  Akt Phosphorylates and Negatively Regulates Apoptosis Signal-Regulating Kinase 1 , 2001, Molecular and Cellular Biology.

[6]  Trevor J Pugh,et al.  Landscape of genomic alterations in cervical carcinomas , 2013, Nature.

[7]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[8]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[9]  J. Testa,et al.  The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. , 1993, Oncogene.

[10]  B. Stanley,et al.  Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. , 2007 .

[11]  M. Socinski,et al.  Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib , 2015, Clinical Cancer Research.

[12]  L. Rubinstein,et al.  Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer , 2015, Investigational New Drugs.

[13]  H. Woo,et al.  Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set , 2010, Molecular Cancer Therapeutics.

[14]  C. Harris,et al.  Tobacco Carcinogen-Induced Cellular Transformation Increases Activation of the Phosphatidylinositol 3′-Kinase/Akt Pathway in Vitro and in Vivo , 2004, Cancer Research.

[15]  E. Kandel,et al.  The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. , 1999, Experimental cell research.

[16]  I. Mellinghoff,et al.  Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[18]  J. Schellens,et al.  Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. , 2002, European journal of cancer.

[19]  A. Hezel,et al.  Phase 2 study of MK‐2206, an allosteric inhibitor of AKT, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005) , 2015, Cancer.

[20]  A. Jakubowiak,et al.  Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[22]  Stephen P. H. Alexander,et al.  Guide to Receptors and Channels (GRAC), 5th edition , 2011, British journal of pharmacology.

[23]  K. Milde-Langosch,et al.  AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. , 2014, Cellular signalling.

[24]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[25]  P. Majumder,et al.  MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.

[26]  Todd R. Golub,et al.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Mammary gland involution is delayed by activated Akt in transgenic mice. , 2001, Molecular endocrinology.

[28]  B. Hemmings,et al.  Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase*♦ , 2004, Journal of Biological Chemistry.

[29]  Moshe Oren,et al.  Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis , 2002, Oncogene.

[30]  Eric C. Holland,et al.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice , 2000, Nature Genetics.

[31]  R. Figlin,et al.  Akt inhibitors in clinical development for the treatment of cancer , 2010, Expert opinion on investigational drugs.

[32]  L. Paz-Ares,et al.  Inhibiting PI3K as a therapeutic strategy against cancer , 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[33]  Victor G Prieto,et al.  Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma , 2009, Clinical Cancer Research.

[34]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H Snowden,et al.  AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K , 2010, Oncogene.

[36]  J. Sparano,et al.  Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. H. Lee,et al.  Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias , 2008, British Journal of Cancer.

[38]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[39]  A. Rezaeian,et al.  Posttranslational regulation of Akt in human cancer , 2014, Cell & Bioscience.

[40]  B. Wang,et al.  Liraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice , 2014, International journal of endocrinology.

[41]  G. Tzivion,et al.  FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. , 2011, Biochimica et biophysica acta.

[42]  A. Carnero,et al.  The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models , 2014, Front. Oncol..

[43]  S. Chandarlapaty,et al.  A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors , 2013, Breast Cancer Research.

[44]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[45]  S. Carter,et al.  The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. , 1975, Cancer treatment reviews.

[46]  J. Paramio,et al.  Molecular determinants of Akt-induced keratinocyte transformation , 2006, Oncogene.

[47]  D. Troyer,et al.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[49]  A. Tolcher,et al.  Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma , 2014, Cancer Chemotherapy and Pharmacology.

[50]  T. Dale,et al.  Protein Kinase B/Akt Acts via Glycogen Synthase Kinase 3 To Regulate Recycling of αvβ3 and α5β1 Integrins , 2004, Molecular and Cellular Biology.

[51]  Juan Wu,et al.  Regulation of Akt signaling activation by ubiquitination , 2010, Cell cycle.

[52]  S. Bose,et al.  The Akt pathway in human breast cancer: a tissue-array-based analysis , 2006, Modern Pathology.

[53]  J. Falke,et al.  Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. , 2008, Biochemistry.

[54]  Jing Li,et al.  Preclinical Development Preclinical Pharmacology of AZD 5363 , an Inhibitor of AKT : Pharmacodynamics , Antitumor Activity , and Correlation of Monotherapy Activity with Genetic Background , 2012 .

[55]  A. Aplin,et al.  Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. , 2010, Cancer research.

[56]  N. Senzer,et al.  Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[58]  Y. Drouet,et al.  Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes , 2012, Breast Cancer Research and Treatment.

[59]  T. Mak,et al.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice , 1998, Current Biology.

[60]  V. Steele,et al.  Targeting the AKT protein kinase for cancer chemoprevention , 2007, Molecular Cancer Therapeutics.

[61]  S. Lowe,et al.  Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. , 2010, Gastroenterology.

[62]  M. Montminy,et al.  CREB Is a Regulatory Target for the Protein Kinase Akt/PKB* , 1998, The Journal of Biological Chemistry.

[63]  James S Blachly,et al.  Targeting PI3‐kinase (PI3K), AKT and mTOR axis in lymphoma , 2014, British journal of haematology.

[64]  C. Lindsley,et al.  Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. , 2007, Current topics in medicinal chemistry.

[65]  K. Anderson,et al.  Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study , 2012, British journal of haematology.

[66]  J A Peters,et al.  Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.

[67]  J. Tabernero,et al.  Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors , 2014, Molecular Cancer Therapeutics.

[68]  E. M. Sale,et al.  Protein kinase B: signalling roles and therapeutic targeting , 2007, Cellular and Molecular Life Sciences.

[69]  C. Du,et al.  Expression of P-Akt, NFkappaB and their correlation with human papillomavirus infection in cervical carcinoma. , 2012, European journal of gynaecological oncology.

[70]  PI3K Inhibitor Improves PFS in BELLE-2 Trial. , 2016, Cancer discovery.

[71]  R. Purohit,et al.  Cancer Associated E17K Mutation Causes Rapid Conformational Drift in AKT1 Pleckstrin Homology (PH) Domain , 2013, PloS one.

[72]  A. Tolcher,et al.  A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  J. Buatti,et al.  Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. , 2009, International journal of radiation oncology, biology, physics.

[74]  L. Wattenberg,et al.  Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard. , 1986, Carcinogenesis.

[75]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[76]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[77]  Rakesh Kumar,et al.  The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. , 2014, Blood.

[78]  T. McGraw,et al.  The Akt kinases: Isoform specificity in metabolism and cancer , 2009, Cell cycle.

[79]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[80]  B. Manning,et al.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. , 2008, The Biochemical journal.

[81]  A. Heinrichs.  DNA repair: The big and the small picture , 2007, Nature Reviews Cancer.

[82]  E. A. Fry,et al.  Recent Progress in Mouse Models for Tumor Suppressor Genes and its Implications in Human Cancer , 2013, Clinical Medicine Insights. Oncology.

[83]  Hong-zhao Li,et al.  Downregulation of FOXO3a Promotes Tumor Metastasis and Is Associated with Metastasis-Free Survival of Patients with Clear Cell Renal Cell Carcinoma , 2014, Clinical Cancer Research.

[84]  Amato J Giaccia,et al.  The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. , 2005, Cancer cell.

[85]  Stephen L. Abrams,et al.  Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. , 2006, Advances in enzyme regulation.

[86]  M. Martinka,et al.  Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Somasekar Seshagiri,et al.  Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers , 2012, Proceedings of the National Academy of Sciences.

[88]  J. Paramio,et al.  Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma. , 2009, Cancer research.

[89]  O. Renner,et al.  Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models , 2010, PloS one.

[90]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[91]  J. Paramio,et al.  Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis. , 2007, Cancer research.

[92]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[93]  C. Deng,et al.  Knockout mouse models and mammary tumorigenesis. , 2001, Seminars in cancer biology.

[94]  L. Platanias,et al.  Cross-Talk between NFkB and the PI3-Kinase/AKT Pathway Can Be Targeted in Primary Effusion Lymphoma (PEL) Cell Lines for Efficient Apoptosis , 2012, PloS one.

[95]  R. Glazer,et al.  Delayed mammary gland involution in MMTV-AKT1 transgenic mice , 2002, Oncogene.

[96]  A. Brunet,et al.  FOXO transcription factors , 2007, Current Biology.

[97]  B. Hemmings,et al.  Life with a Single Isoform of Akt: Mice Lacking Akt2 and Akt3 Are Viable but Display Impaired Glucose Homeostasis and Growth Deficiencies , 2006, Molecular and Cellular Biology.

[98]  P. Chapman,et al.  Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma. , 2015 .

[99]  M. Scaltriti,et al.  Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer , 2015, Expert opinion on investigational drugs.

[100]  Anandita Rajpurohit,et al.  Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine , 2012, Oncotarget.

[101]  J. Nemunaitis,et al.  Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  Carmen Blanco-Aparicio,et al.  PTEN, more than the AKT pathway. , 2007, Carcinogenesis.

[103]  R. Cardiff,et al.  Activation of Akt (Protein Kinase B) in Mammary Epithelium Provides a Critical Cell Survival Signal Required for Tumor Progression , 2001, Molecular and Cellular Biology.

[104]  W. Sellers,et al.  Akt-regulated pathways in prostate cancer , 2005, Oncogene.

[105]  R. Lotan,et al.  Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. , 2003, Journal of the National Cancer Institute.

[106]  Jing Li,et al.  Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background , 2012, Molecular Cancer Therapeutics.

[107]  Martin E. Gleave,et al.  Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. , 2015, European urology.

[108]  A. Hsieh,et al.  Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC). , 2014 .